TY - JOUR
T1 - Reduction in the Risk of Prostate Cancer
T2 - Future Directions After the Prostate Cancer Prevention Trial
AU - Crawford, E. David
AU - Andriole, Gerald L.
AU - Marberger, Michael
AU - Rittmaster, Roger S.
N1 - Funding Information:
Medical writing support in the preparation of this manuscript was provided by Katherine Carpenter and was funded by GlaxoSmithKline.
PY - 2010/3
Y1 - 2010/3
N2 - The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk-specifically, the potential role of 5α-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5α-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
AB - The landmark Prostate Cancer Prevention Trial (PCPT) generated interest in the potential health benefits and cost of reducing prostate cancer risk-specifically, the potential role of 5α-reductase inhibitors. However, the PCPT raised several unanswered questions, including the cause and significance of the increased incidence of high-grade tumors associated with finasteride. In the present study, we review the PCPT findings and unanswered questions, next steps in this field, and ongoing prostate cancer prevention trials addressing these unanswered questions. Particular emphasis is placed on the design of the second large-scale trial of a 5α-reductase inhibitor, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
UR - http://www.scopus.com/inward/record.url?scp=77649179284&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2009.05.099
DO - 10.1016/j.urology.2009.05.099
M3 - Review article
C2 - 20035983
AN - SCOPUS:77649179284
SN - 0090-4295
VL - 75
SP - 502
EP - 509
JO - Urology
JF - Urology
IS - 3
ER -